Organogenesis Holdings

Organogenesis Holdings, Inc. is a regenerative medical company. It focuses on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Organogenesis reports 11% revenue growth in Q1 2023

Organogenesis reported solid revenue growth driven by Advanced Wound Care products, but faced challenges with a net loss for the quarter. The company's operational progress and active participation in industry events demonstrate a commitment to innovation and market presence. Looking ahead, the focus on measured growth and product development presents opportunities for future success.

Organogenesis reports Q2 revenue dip, focuses on growth opportunities

Organogenesis reported a slight decrease in net revenue but highlighted strong demand for certain products. The company faces uncertainty due to LCDs affecting Medicare reimbursement but is actively working to mitigate the impact and capitalize on growth opportunities.

Organogenesis reports 7% decrease in Q3 revenue, focuses on customer reengagement

Organogenesis Holdings Inc. faces a decrease in net revenue due to business disruption from local coverage determinations, but is actively working to reengage with customers and correct misinformation. Despite challenges, the company expects to bring back a majority of accounts by the end of the year and sees opportunities for growth through reestablishing products in the market.

ORGO reports Q4 revenue challenges, eyes growth through new products

ORGO's Q4 2023 earnings call highlighted revenue challenges, cost management efforts, and a focus on growth opportunities in 2024. Despite a decrease in net revenue, the company remains optimistic about new product launches and strategic investments driving future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Organogenesis Holdings, Inc. is a regenerative medical company, which engages in the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.

Organogenesis (ORGO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Organogenesis (ORGO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

CANTON, Mass., July  23, 2020  (GLOBE NEWSWIRE) --  Organogenesis Holdings Inc.  (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that the latest advanced wound care research on its Apligraf®, Affinity®, Dermagraft®, Nushield® and PuraPly® AM product lines will be showcased at the 2020 Symposium on Advanced Wound Care (SAWC) Spring | Wound Healing Society Virtual Experience, held July 24-26.

Latest Advanced Wound Care Innovations and Research from Organogenesis to be Highlighted at SAWC Spring | WHS 2020 Virtual Meeting

CANTON, Mass., July  15, 2020  (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported preliminary revenue results for the three months ended June 30, 2020. 

Organogenesis Holdings Inc. Reports Preliminary Revenue Results for Second Quarter 2020

Organogenesis Holdings, Inc. (ORGO) CEO Gary Gillheeney on Q1 2020 Results - Earnings Call Transcript

Organogenesis (ORGO) delivered earnings and revenue surprises of -33.33% and 0.71%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Organogenesis (ORGO) Reports Q1 Loss, Tops Revenue Estimates

CANTON, Mass., April  13, 2020  (GLOBE NEWSWIRE) --  Organogenesis Holdings Inc.  (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced it will support a series of virtual education events geared toward clinicians and other wound care and surgical stakeholders during the month of April.  

Organogenesis Announces Virtual Education Events for April

Organogenesis Holdings has been struggling lately, but the selling pressure may be coming to an end soon.

Organogenesis Sees Hammer Chart Pattern: Time to Buy?

Organogenesis Holdings Inc. (ORGO) CEO Gary S.

Organogenesis: Undervalued And Promising Investment Opportunity For 2020

Pure Storage

VirnetX

Find out what punished these unfortunate stocks.

Why Pure Storage, VirnetX Holding, and Organogenesis Holdings Slumped Today

The regenerative medicine company announced the pricing of a public stock offering.

Here's Why Organogenesis Fell as Much as 23.1% Today

News for Organogenesis Holdings Stock (ORGO)